Switching from natalizumab to fingolimod : A randomized, placebo-controlled study in RRMS

Neurology

Volumn 85, Issue 1, 2015, Pages 29-39

  Kappos, Ludwig ^a   Radue, Ernst Wilhelm ^b   Comi, Giancarlo ^d   Montalban, Xavier ^e   Butzkueven, Helmut ^f   Wiendl, Heinz ^g   Giovannoni, Gavin ^h   Hartung, Hans Peter ⁱ   Derfuss, Tobias ^a   Naegelin, Yvonne ^a   Sprenger, Till ^a,b,c   Mueller Lenke, Nicole ^b   Griffiths, Sarah ^j   Von Rosenstiel, Philipp ^k   Gottschalk, Rebecca ^k   Zhang, Ying ^k   Dahlke, Frank ^k   Tomic, Davorka ^k  

^a Clinical Research and Biomedicine   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF MILAN   (Italy)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g UNIVERSITY OF MÜNSTER   (Germany)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j OXFORD PHARMAGENESIS LTD   (United Kingdom)

^k NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; METHYLPREDNISOLONE; NATALIZUMAB; PLACEBO; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ACUTE CHOLECYSTITIS; ADULT; ARTICLE; BRADYCARDIA; CHOLELITHIASIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEPRESSION; DISEASE ACTIVITY; DISEASE CONTROL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INFUSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECG ABNORMALITY; EPILEPSY; EXPANDED DISABILITY STATUS SCALE; FAINTNESS; FEMALE; FEMUR FRACTURE; HEADACHE; HEART RATE; HOSPITALIZATION; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MYALGIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX PAIN; PARALLEL DESIGN; PERSONALITY DISORDER; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; RHINOPHARYNGITIS; SINUSITIS; SUICIDE; T WAVE INVERSION; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG SUBSTITUTION; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATALIZUMAB; PROPYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPHINGOSINE;

EID: 84936999643     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001706     Document Type: Article

References (31)

1. FDA. Tysabri US prescribing information. Revised December 2013. Available at: http://www.accessdata.fda. gov/drugsatfdádocs/label/2013/125104s840s847s889lbl. pdf. Accessed February 12, 2014
2. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-Associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880
3. FDA. Tysabri US prescribing information. Revised May 2013. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125104s813lbl.pdf. Accessed November 22, 2013
4. Martinelli V, Colombo B, Dalla Costa G, et al. Recurrent disease-Activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. Mult Scler Epub 2013 Jun 17
5. OConnor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858-1865
6. Cohen M, Maillart E, Tourbah A, et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol 2014; 71: 436-441
7. Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-Term relapse. Neurology 2014; 82: 1204-1211
8. Gueguen A, Roux P, Deschamps R, et al. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 85: 1038-1040
9. Fox RJ, Cree BA, De Seze J, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014; 82: 1491-1498
10. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9: 883-897
11. Novartis Pharmaceuticals Corp. Gilenya US Prescribing Information. Revised May 2012. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf. Accessed April 16, 2014
12. European Medicines Agency. Summary of product characteristics. Updated June 18, 2012. Available at: http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002202/WC500104528.pdf. Accessed April 16, 2014
13. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415
14. Comi G, Gold R, Dahlke F, et al. Relapses in patients treated with fingolimod after previous exposure to natalizumab. Mult Scler 2015; 21: 786-790. doi: 10.1177/1352458514549404
15. Nixon RM, Bergvall N, Sfikas N, et al. Indirect comparisons of oral fingolimod versus natalizumab on measures of disease freedom in patients with multiple sclerosis, based on results from FREEDOMS and AFFIRM. Poster presented at AAN 2013, San Diego, CA, 2013; P01.209
16. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302
17. Kappos L, Radue EW, OConnor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401
18. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice. Available at: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf. Accessed May 18, 2015
19. WorldMedical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed October 4, 2013
20. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10: 745-758
21. Havla J, Tackenberg B, Hellwig K, et al. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol 2013; 260: 1382-1387
22. Sempere AP, Martin-Medina P, Berenguer-Ruiz L, et al. Switching from natalizumab to fingolimod: an observational study. Acta Neurol Scand 2013; 128: e6-e10
23. de Seze J, Ongagna JC, Collongues N, et al. Reduction of the washout time between natalizumab and fingolimod. Mult Scler 2013; 19: 1248
24. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59: 743-747
25. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008; 71: 1261-1267
26. Claes N, Dhaeze T, Fraussen J, et al. Compositional changes of B and T Cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study. PLoS One 2014; 9: e111115. doi: 10.1371/journal. pone.0111115
27. Grützke B, Hucke S, Wildemann B, et al. Fingolimod treatment promotes regulatory B-cell phenotype and function in multiple sclerosis. J Neuroimmunol 2014; 275: 42-43
28. Putzki N, Clifford DB, Bischof D, et al. Characteristics of PML cases in multiple sclerosis patients switching to fingolimod from natalizumab. Mult Scler 2014; Abstract FC3.1
29. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545-556
30. Kappos L, Cohen J, Collins W, et al. Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings. Mult Scler Relat Disord 2014; 3: 494-504
31. Centonze D, Rossi S, Rinaldi F, Gallo P. Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 2012; 79: 2004-2005